The seminar will provide an overview of UNODC’s work on the treatment of drug use disorders with a specific focus on efforts that support health and justice collaboration to increase access to health services for people with drug use disorders in contact with the criminal justice system.
BACKGROUND: The abuse of psychoactive prescription drugs has become increasingly common in the Czech Republic. These drugs include sedatives, hypnotics, anxiolytics (benzodiazepines and Z-hypnotics), and opioids. Patients with an addiction to these prescription drugs exhibit symptoms associated with long-term use, particularly psychological and somatic problems, sleep disturbances, impaired cognitive functioning, and irritability.
There is increasing interest and evidence for the use of cannabinoid medications in the treatment of cannabis use disorder, but little examination of the correlates of successful treatment.
There is a higher prevalence of substance use disorder (SUD) among justice-involved children (JIC). It is critical to ensure that JIC who report current use are referred for SUD assessment and potentially life-saving treatment services.
COVID-19 dramatically limited the scale and scope of local health department (LHD) work, redirecting resources to the response. However, the need for essential public health services—including substance use prevention—was not reduced.
Healthcare workers across the world have risen to the demands of treating COVID-19 patients, potentially at significant cost to their own health and wellbeing. There has been increasing recognition of the potential mental health impact of COVID-19 on frontline workers and calls to provide psychosocial support for them.
This month on November 9th, 2022, the International Narcotics and Law Enforcement Affairs (INL) DDR Partners meeting offered a discussion on quality assurance and included two presentations:
Contingency management (CM) is a psychological treatment based on operant conditioning. It consists of providing incentives in exchange for achieving a target behaviour such as abstinence or other treatmentrelated variables (e.g. session attendance, adherence to medication). The objective of this article was to introduce the rationale of CM for substance use and, more specifically, for smoking cessation.